- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02453698
Stimulant Effects on Brain Activity
Stimulant Effects on Brain Activity During the Stop Signal Task
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Methylphenidate (MPH) is the stimulant medication most commonly used in the treatment of attention deficit hyperactivity disorder (ADHD). MPH suppresses the reuptake of dopamine by blocking dopamine transporter, which is elevated in ADHD. However, the precise mechanism by which suppressed dopamine transporter activity relieves ADHD symptoms is not fully understood, partly because dopamine pathways are implicated in various processes that could play a role in the deficits of ADHD and other disorders. MPH-induced dopamine variation has extensive effects in the brain and influences various executive functions in unknown ways.
Hypotheses:
Inhibitory Control: The investigators predict that MPH should increase the top-down activity in right dorsolateral prefrontal cortex associated with response restraint during go-phases and bottom-up activity in caudate and right inferior frontal cortex associated with response cancellation during successful stop trials. A greater modulation of top-down or bottom-up activity would imply a selective effect of MPH on one pathway over the other.
Error Processing: The investigators predict that MPH should increase the intensity of deactivation in the bottom-up dopamine pathway on error detection (substantia nigra, dorsal striatum and ACC), and increase the intensity of deactivation in the top-down pathway on post-error slowing (caudal OFC, ventral striatum, ventral substantia nigra). A greater modulation of top-down or bottom-up activity would imply a selective effect of MPH on one pathway over the other.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- The Hospital for Sick Children
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria
- Healthy, non-smoking, male and female volunteers, between 18 to 35 years of age inclusive, right-handed
- Body Mass Index that is within 18.5-29.9 kg/m2, inclusive
- Healthy, according to the medical history, vital signs, and physical examination (within 2 years prior to study enrollment)
- Systolic blood pressure between 100-140 mmHg, inclusive, and diastolic blood pressure between 60-90 mmHg, inclusive, and heart rate between 50-100 bpm, inclusive, unless deemed not clinically significant by the Principal Investigator/ Sub-Investigator?
- Capable of giving written informed consent prior to receiving any study medication
Female subjects must fulfill at least one of the following:
- Agree to avoid pregnancy and use medically acceptable method of contraception from at least 30 days prior to the study, during the study, and until 30 days after the study has ended (last study procedure). Medically acceptable methods of contraception include oral contraceptives, hormonal patch, implant or injection intrauterine device, or double barrier method (condom with foam or vaginal spermicidal suppository, diaphragm with spermicide). Complete abstinence alone can be used as a method of contraception.
- Be surgically sterile for a minimum of 6 months
- Post-menopausal for a minimum of 1 year
Exclusion Criteria
- Known history or presence of any clinically significant hepatic (e.g. hepatic necrosis, jaundice, hepatobiliary disease), renal, gastrointestinal (e.g. peptic ulcer), cardiovascular (e.g. angina, myocardial infarction), cerebrovascular, pulmonary, endocrine (e.g. diabetes, hypophosphatemia), immunological, musculoskeletal (e.g. rhabdomyolysis, myopathy), neurological, psychiatric, dermatological, or hematological disease or condition
- Presence of any clinically significant illness within 30 days prior to dosing
- Presence of any significant physical or organ abnormality
Known history or presence of:
- Alcohol abuse or dependence within one year prior to drug administration
- Drug abuse or dependence
- Hypersensitivity to methylphenidate or other medications
- Gout
- Food allergies and/or presence of any dietary restrictions
- Severe allergic reactions (e.g. anaphylactic reactions, angioedema)
- Participation in another clinical trial or receiving an investigational drug within 30 days of the study commencement or during the study
- Use of any prescription medication within 14 days prior to drug administration (except for hormonal contraceptives)
- Use of any over-the-counter medications (including herbal and/or dietary supplements and/or teas) within 14 days prior to drug administration (except for spermicidal/barrier contraceptive products)
- Any major surgery within 6 months prior to the start of the study
- Pregnant or lactating
- Lactose intolerance
- Contraindication for MRI (using hospital's standard screening procedure)
- Smoking
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Kontrollgrupp
|
Lactose Placebo
|
Experimentell: Metylfenidat
|
oral dose of methylphenidate.
The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, & Gatley, 2002) and adults with ADHD (Aron et al., 2003).
MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Neural activity assessed using fMRI
Tidsram: 7 days
|
Assessed using fMRI
|
7 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Russell Schachar, MD, The Hospital for Sick Children, Toronto Canada
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1000020845
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Friska volontärer
-
University of MiamiJames and Esther King Biomedical Research ProgramAvslutadHealthy Lifetime Icke-rökareFörenta staterna
-
University of LeicesterNational Institute for Health Research, United KingdomAvslutadPatienter med hjärtsvikt och konserverad ejektionsfraktion - HFpEF | Patienter med hjärtsvikt med reducerad ejektionsfraktion - HFrEF | Healthy Controls Group - ålders- och könsmatchad
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvslutadParkinsons sjukdom | Healthy Controls Group - ålders- och könsmatchadFrankrike
Kliniska prövningar på Methylphenidate
-
Rhodes Pharmaceuticals, L.P.OkändAttention Deficit Disorder med hyperaktivitetFörenta staterna
-
Children's Hospital Medical Center, CincinnatiNational Institute of Mental Health (NIMH)AvslutadADHD – kombinerad typ | ADHD - ouppmärksam typFörenta staterna